Neuraxpharm

To mark the holiday season and the close of another successful year, today we have published a video thanking all those who work tirelessly to fulfil #Neuraxpharm’s purpose: improving the quality of life for patients living with #CNS disorders.    Within the Neuraxpharm family, we are constantly reminded of how much we count on each other to make a difference to those who count on us.   In the spirit of this commitment, Neuraxpharm is pleased to make a donation to Michael Foundation / Stiftung Michael in Germany. This association is dedicated to research and studies on epilepsy. Its mission focuses on the scientific investigation of the causes of seizure disorders, the most effective treatment methods, and addressing both the individual and social impacts of these conditions. Besides, the foundation supports qualification programs for professionals in epileptology. Through this donation, we reaffirm our dedication to making a positive impact on the lives of those most in need.   As we celebrate the season of giving and look forward to the year ahead, we sincerely thank all those at Neuraxpharm for their invaluable contribution and we wish them joy, warmth and moments of connection with their loved ones.   Merry Christmas and a prosperous New Year! We hope it is filled with health, happiness and fulfilment as, together, we count on each other to continue growing and making an even greater impact in the year to come.

Today we have announced a strategic alliance with Pharmathen to co-develop new long-acting injectable (LAI) therapies within the psychiatry field under Pharmathen’s long-acting therapeutic technologies (LATT) program. Our CEO, Jörg Thomas Dierks, commented on the agreement highlighting that, "These are well established therapies, but we are bringing them to the market in a new format, which will offer patients greater flexibility and control in how they manage what are often challenging conditions." Pharmathen, one of the largest pharmaceutical companies in Greece, has a proven track record in the development and launch of LAI products globally, and will be the technological, manufacturing and supply partner. #Neuraxpharm, with our long-proven commercialisation expertise for CNS products in Europe, will register and market the products across Europe and other direct Neuraxpharm markets. Find out more about the strategic co-development agreement and Pharmathen's LATT program in the press release linked in the comments. #CNS #pharma #pharmaceuticals

Very encouraging news today as #Neuraxpharm and Minoryx Therapeutics announce that the NEXUS trial, designed to evaluate the efficacy and safety of leriglitazone in pediatric patients with cerebral Adrenoleukodystrophy (cALD), has met its primary endpoint. Results have shown that leriglitazone, which was well tolerated in all participants, not only arrests the condition but also clinical progression in children.    Our CEO, Dr Jörg Thomas Dierks, commented: “cALD is a very serious neurological disorder with devastating outcomes for patients and their families. The results from this trial are extremely encouraging and we are fully committed to working with Minoryx to swiftly provide patients with an effective new treatment for this otherwise fatal and cruel disease.”   Based on these successful results, Minoryx and Neuraxpharm have begun compiling the regulatory file for marketing authorization application (MAA) submission to the European Medicines Agency (EMA).   Read more details about the trial in the press release linked below. #CNS #cALD #pharmaceuticals #pharma

Neuraxpharm's Swiss team attended the SPS Swiss Pain Society and Swiss Society for Gender Health Network Annual Congress 2024, focused on this year's topic: Sex and Gender Disparities in Pain.   Held in Aarau from 14-15 November, the event provided valuable insights from a variety of roundtables and workshops to discuss the importance of providing more personalized and effective pain relief solutions for patients with the #healthcare professionals who attended.   Neuraxpharm works together with healthcare professionals and scientific communities to improve the wellbeing of patients with neurological and psychiatric disorders.   #pharma #pharmaceuticals #pain #neurology #CNS #ZNS

Neuraxpharm reports another year of sustained growth and international expansion, having established itself as a leading European CNS-focused pharma company since its rebranding in 2018. Over the last year, we have further expanded our footprint across Europe and beyond, and have broadened our portfolio to become an innovative company. Our CEO, Dr Jörg Thomas Dierks reflects on Neuraxpharm's progress and comments: "After a year that has seen Neuraxpharm deliver sustained growth from our portfolio, alongside continued international geographical expansion, we look forward to bringing further important and innovative treatments to patients all over the world.” If you are joining the Jefferies London Healthcare Conference next week, make sure to attend Dr Dierks' presentation on Tuesday 19th November at 14:30 GMT in the Executive Lounge. Read about our year of international expansion with a focus on #innovation and strategic transformation in the press release linked in the comments. #CNS #pharma #pharmaceuticals #Neuraxpharm

During the National Congress of the Italian Society of Neurology (SIN) - which was held in Rome from 9 to 12 November, Neuraxpharm had presented to an audience of national neurologists the monoclonal antibody for the treatment of multiple sclerosis. The introduction of this treatment shows the strong Neuraxpharm commitment on central nervous system pathologies, enriching an increasingly diversified portfolio, oriented towards the benefit of patients, Neuraxpharm with 28 research projects in development, wants to increase and consolidate its leadership on central nervous system. #Neuraxpharm #SIN2024 #Neurology #Innovation ------------------------- In occasione del congresso SIN (società italiana di neurologia) che si è tenuto a Roma dal 9 al 12 Novembre, Neuraxpharm ha presentato ad una platea di neurologi provenienti da tutto il territorio nazionale, l’anticorpo monoclonale indicato per il trattamento della sclerosi multipla. L'introduzione di questo trattamento consolida il focus di Neuraxpharm sulle patologie del sistema nervoso centrale arricchendo un portafoglio sempre più diversificato, finalizzato al benessere del paziente e con 28 progetti di ricerca in fase di sviluppo. #Neuraxpharm #SIN2024 #Neurologia #Innovazione

Neuraxpharm's CEO, Dr Jörg Thomas Dierks, will be presenting at Jefferies London Healthcare Conference next week at the Waldorf Hilton.   Dr Dierks will be presenting on Tuesday 19th November at 14:30 GMT in the Executive Lounge, followed by a moderated Q&A.   The conference marks its 15th anniversary and is the largest healthcare-dedicated conference in Europe, bringing together leading global, public and private companies across the #healthcare industry.   Connect with Neuraxpharm at the event or reach out to schedule a meeting.   #JefferiesHealthcare #JefferiesHealthcareConference #CNS #pharma #pharmaceuticals

The German Neuraxpharm team is proud to welcome neurologists at the DGN Congress, the largest congress for neurologists in Germany, which is taking place in Berlin at the moment. Neuraxpharm is committed to be one of the biggest CNS providers not only in Germany but in Europe, offering a broad range of treatment options for diseases concerning the CNS. Come and join us at our booth and get to know our latest innovations. The team is looking forward to welcome you. #dgnkongress2024 #Neuraxpharm #CNS #Neurology

Final video release! Peace of Mind - Overcoming Anxiety: What's like to have anxiety? Our campaign, developed in partnership with Maudsley Learning, aims to raise awareness and understanding of anxiety, a condition that affects millions of people around the world. We present the final video in our series, which focuses on the patient perspective and the warning signs that can help us identify when we are experiencing anxiety. By sharing this video, you help to educate and inform our community, fostering a more understanding and supportive environment. Visit our website to find out more about the initiative and watch all the videos: https://lnkd.in/ebVxG6pc #mentalhealthawareness #PeaceOfMind #MentalHealth #Anxiety #CNS #Neuraxpharm

Neuraxpharm, European leader in production and development of central nervous system disorders drugs, participates at SIN 2024 Congress (Italian Society of Neurology) which will be held in Rome at the "La Nuvola" conference center from 9 to 12 November 2024. “Our presence as Neuraxpharm Italia at SIN 2024 Congress is consistent with our total commitment in the area of Central Nervous System pathologies. Today our participation is even more important since we will present to the scientific community an infusion therapy for people suffering from Multiple Sclerosis – reports Serena F.L. Zucchetta, Country Manager of Neuraxpharm Italia, and underlines Neuraxpharm's commitment in Brain & Mental Health with a 100% CNS pipeline with currently 28 research projects in development. “There is still a lot to do in this area, research is fundamental when we consider that in Italy more than half of the population is affected, in various ways, by a neurological or mental pathology, numbers destined to grow with the aging of the population population and the statistics that involve more and more young people are worrying." Neuraxpharm will be happy to meet you at the SIN congress in its exhibition space designed to be increasingly supportive of the Neurology Specialist and the patients they care for. #Pharma #Neuraxpharm #CNS #Neurology -------------------------------------- Neuraxpharm, leader europeo nella produzione e sviluppo di farmaci per i disturbi del sistema nervoso centrale, parteciperà al Congresso SIN 2024 (Società Italiana di Neurologia) che si terrà a Roma presso il centro congressi "La Nuvola" dal 9 al 12 Novembre 2024. “La nostra presenza come Neuraxpharm Italia al Congresso SIN 2024 è coerente col nostro impegno totale nel settore delle patologie del Sistema Nervoso Centrale. Oggi la nostra partecipazione è ancor più importante poiché presenteremo alla comunità scientifica una terapia infusionale per le persone che soffrono di Sclerosi Multipla – riferisce Serena F.L. Zucchetta, Country Manager di Neuraxpharm Italia, e sottolinea l’impegno di Neuraxpharm in Brain & Mental Health con una pipeline al 100% CNS con attualmente 28 progetti di ricerca in sviluppo. “C’è ancora moltissimo da fare in questo ambito, la ricerca è fondamentale quando si pensa che in Italia più della metà della popolazione è colpita, a vario titolo, da una patologia neurologica o mentale, numeri destinati a crescere con l’invecchiamento della popolazione e preoccupano le statistiche che vedono coinvolti sempre più giovani”.   Neuraxpharm sarà lieta di incontrarvi al congresso SIN presso il proprio spazio espositivo pensato per essere sempre più a supporto dello Specialista in Neurologia e dei pazienti di cui si prende cura. #Pharma #Neuraxpharm #CNS #Neurologia